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Outcome Following Loss of Primary Patency After Endovascular In-
tervention of Superficial Femoral and Popliteal Arteries
Maciej L Dryjski1,2, Monica O’Brien-Irr2, Hasan Dosluoglu1, Linda Har-
ris1,2. 1University at Buffalo, Buffalo, NY; 2Kaleida Health, Buffalo, NY
Objective: To evaluate outcomes following loss of primary patency
(LPP) in superficial femoral (SFA) and popliteal (Pop) arteries treated by
endovascular intervention (EVI)
Methods: The medical records of all SFA/Pop EVI performed by 2
Vascular Surgeons between 2005- 2008 were reviewed to identify LPP
defined as occlusion or need for re-intervention documented by duplex or
angiography. TASC II, EVI type, Rutherford Score (RS) and Rutherford
Improvement Scores (RIS) were recorded. Analysis was completed with
SPSS 15.
Results: LPP occurred in 38 patients (31%) at 8.6  5.4 months.
Twenty-four (63%) of these patients had EVI for critical limb ischemia
(Rutherford Class 4-6). Mean follow up (FU) was 20 11 months. Neither
TASC II, RS at primary EVI (PEVI) or EVI type had significant impact on
RIS at LPP. RIS at LPPwas worse than before PEVI in 55%. Re-intervention
was performed in 79% of LLP patients. Patients who never showed signifi-
cant improvement between PEVI and LPP were unlikely to improve at FU
(Table I) despite a trend to undergo multiple re-interventions (55% vs. 13%;
p0.06). Survival and limb salvage at 24 months were 75% and 92%.
Healing occurred in 46% of tissue loss patients at 11.9  11.6 months.
Conclusion: EVI of the SFA/Pop arteries are not benign procedures.
LPP occurred in nearly 1/3 of patients and 55% of those patients became
worse than prior to PEVI. Despite reasonable limb salvage, healing occurred
in only 46% and was delayed. Aggressive re-intervention after PLL may not
improve outcome in patients who did not demonstrate significant interval
improvement after PEVI.
Table 1
Classification:PEVI/LPP
interval
Improved RIS @ FU
entire group N(%)
Improved RIS@ FU
re-intervenedN(%)
Improvement¡
Worsening
19(82%) 15(88%)
Unchanged/ Worsening 3(20%) 2(15%)
P Value (Significance) 0.013 0.007
Author Disclosures: M.L. Dryjski, None; M. O’Brien-Irr, None; H.
Dosluoglu, None; L. Harris, None.
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Contemporary Results with Endovascular Therapy for Acute Limb
Ischemia
Ramyar Gilani, Mohsen Bannazadeh, James F Bena, Timur P Sarac, Vikram
S Kashyap. The Cleveland Clinic Foundation, Cleveland, OH
Objective: Endovascular therapies play an increasing role in the treat-
ment of acute limb ischemia. The purpose of this study was to assess
outcomes in patients treated for acute limb ischemia (ALI) with intra-arterial
thrombolysis and/or percutaneous mechanical thrombectomy (PMT).
Methods:Consecutive patients (n 76) with ALI of the lower extrem-
ities treated via intra-arterial methods between January 1, 2005 and Decem-
ber 31, 2006 were identified and reviewed. Overall estimates of patency,
limb salvage, and survival at 1 and 2 years were made using Kaplan-Meier
estimation. Hazard ratios from Cox proportional hazards models were used
to estimate differences in risk between groups for patency and survival.
Results: Patients with ALI (82 limbs) presenting with native artery or
graft thrombosis (76%) underwent thrombolysis and PMT (46%) under
local anesthesia (96%) for an average of 1.6 days. Adjunctive procedures were
required in 94% of patients to treat the culprit lesion with solely open
revascularization in 16%. One patient had a major bleeding episode, but
there was no intracranial hemorrhage in this cohort. 30-day amputation and
mortality rates were 14% and 6%. Primary patency at 1 and 2 years were
52.1% (95% CI, 39.3- 64.8), and 41.6% (95% CI, 27.9-55.4), while second-
ary patency rates at 1 and 2 years were 74.6% (95% CI, 63.7-85.5), and
67.5% (95% CI, 55.1-80.0) respectively (median follow up22.5 months).
Limb salvage at 1 and 2 years was 86.5% (95% CI, 77.7-95.3) and 81.9%
(95% CI, 71.5-92.3). Patients on dialysis (HR, 3.82; 95% CI, 2.22-6.59;
P0.001) and elevated creatinine levels (HR 1.16; 95% CI, 1.05- 1.29;
P0.004) were associated with primary patency loss. Overall survival at 1
and 2 years was 83.4% (95%CI, 74.4- 92.4) and 81.6% (95%CI, 72.1-91.1).
Women were at an increased risk for mortality (HR, 16.93; 95% CI,
2.18-131.58; P0.007) while those with COPD (HR, 3.12; 95% CI,
0.93-0.45; P0.065) trended towards increased risk.Conclusions: ALI remains a challenging clinical entity. Endovascular
therapy is a safe and durable treatment option for patients presenting with
lower extremity ALI. Patients with impaired renal function are associated
with worse long term patency outcomes. Female patients are associated with
decreased overall survival.
Author Disclosures: R. Gilani, None; M. Bannazadeh, None; J.F. Bena,
None; T.P. Sarac, None; V.S. Kashyap, None.
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Results with Viabahn-Assisted Subintimal Recanalization for Severe
Superficial Femoral Artery Occlusive Disease
Joseph R Schneider1, Michael J Verta, Jr.2, Marc J Alonzo3, David Hahn3,
Nilseh H Patel1, Stanley Kim1. 1Central DuPageHospital, Winfield, IL; 2St.
Mary’s Good Samaritan Hospital, Mount Vernon, IL; 3Northshore Univer-
sity Healthcare, Evanston, IL
Objectives: Many investigators including Transatlantic Inter-Society
Consensus (TASC) recommend against primary endovascular treatment for
severe (TASC C and D) superficial femoral artery (SFA) disease. Vein bypass
is preferable, but may not be appropriate due to comorbidities or lack of
suitable vein. This study reviews our results with Viabahn stent graft-assisted
subintimal recanalization (VASIR) for TASC C and D SFA atherosclerosis.
Methods:Thirteenmales and fourteen females, mean age 7311 years
underwent 28 VASIR for severe (TASC C 8/28, TASC D 20/28; 4/28 no
continuous infrapopliteal run-off artery) SFA disease. Indications were clau-
dication (14/28 limbs), ischemic rest pain (6/28), and tissue loss (8/28).
VASIR was chosen instead of bypass due to comorbidities or lack of vein.
Patients received aspirin and, if not already taking warfarin, they also received
clopidogrel. Patients were examined with ABI and duplex scan at 1 month,
then every 3 months after VASIR.
Results VASIR was technically successful in all. ABI averaged .47.17
pre-procedure, .89.20 post-procedure, and increased by .15 or more in
every case.Median follow-up is 20months. There were 3 perioperative (30
days) and 7 later failures including revision prior to any thrombosis. One
patient required amputation. Four have died, two with patent grafts, none
from causes related to VASIR, all more than 30 days post-VASIR. Estimated
one year primary and secondary patency were 7011% and 7310%. Failure
was not significantly associated with indications, comorbidities, or runoff
status. There was a clear distinction between patients with early failure and
the rest of the patients. None of 8 patients with failure in the first 8 months
after surgery has a patent graft. However, of 17 grafts primarily patent at 8
months, only two have failed (one thrombosed, one required preemptive
balloon angioplasty). Furthermore, although warfarin was not prescribed as
part of the protocol, no patient taking warfarin before and who resumed
warfarin after VASIR (n4) suffered failure.
Conclusions: Despite significant early failures, we found VASIR to be
durable in those who did not suffer early failure. VASIR is an acceptable
alternative to vein bypass in selected patients with severe SFA disease.
Warfarin may be valuable to reduce the risk of failure after VASIR.
Author Disclosures: J.R. Schneider, None; M.J. Verta, None; M.J.
Alonzo, None; D. Hahn, None; N.H. Patel, None; S. Kim, None.
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Major Limb Amputations Have Decreased in New York State During
the Last Decade
Roman Nowygrod1, Natalia N Egorova2, Stephanie Guillerme2, Nicholas
Morrissey1, Annetine CGelijns2, James FMcKinsey3. 1Columbia University
Medical Center, New York, NY; 2Mount Sinai School of Medicine, New
York, NY; 3Columbia University Medical Center, New York, NY
Background:Over the past decade, dramatic shifts in the management
of vascular disease have increased safety and reduced mortality. This study
examines the impact of these changes on limb salvage success.
Methods:NY State in-patient hospital discharge data from 1998-2007
were queried for patients who underwent either open or endovascular
(endo) lower extremity revascularization procedures (LER) or amputation-
s.Patients were selected by cross referencing ICD9 diagnostic and proce-
dural codes. Proportions were analyzed by chi-squared analysis, continuous
variables by t test and trends by the Cochran-Armitage test.
Results: Over time the combined rate of LE surgery decreased by 13%,
with major shifts occurring in the type of surgery. While the per capita
(100,000 population, age40) volume for endo LER doubled (34.6 to
71.7), the number of major amputations and open LER declined by 38%
(44.5 to 30.3) and 40% (104.2 to 62.2), respectively. Interventions for
patients with critical ischemia (CI) declined by 17% (88.1 to 73.5), but those
for claudication increased by 61% (17.7 to 28.6). Endo LER interventions
for both claudication and CI nearly tripled (286%, 271%). Though the total
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capita decreased by 14%, compared to a 20% decline in other age groups.
The incidence of significant comorbidities has substantially increased; for
claudicants: diabetes by 19%, HTP 30%, COPD 40%, CAD 21% and renal
230%; for patients with CI: HTP, COPD, and CAD incidence was higher
(23%, 32%, 8% respectively) but diabetics decreased by 6%. Cardiac, respira-
tory and infection complications after amputation have increased by 29%,
28% and 10%. For LER, respiratory complications increased 9% but cardiac
and infection complications actually decreased (8 and 27%) Similar trends
were observed for patients with combined LER and amputation. Length of
stay (LOS) declined significantly in all groups with an overall decrease of 30%
(p.05).
Conclusion: Despite the fact that patients, whether treated for claudi-
cation or CI, are sicker, older and havemore complications, the rate of major
amputations and LOS has significantly decreased due presumably to wide-
spread and successful use of endo LER and/or to earlier interventions driven
by the safety of endo LER.
Author Disclosures: R. Nowygrod, None; N.N. Egorova, None; S.
Guillerme, None; N. Morrissey, None; A.C. Gelijns, None; J.F. McKin-
sey, None.
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An Algorithm for Optimal Utilization of Percutaneous Closure Devices
Samuel S Ahn1, Julia F Chen1,2, Christopher Kim1, Kevin Peng1. 1University
Vascular Associates, Los Angeles, CA; 2DFW Vascular Group, Dallas, TX
Purpose: To introduce an algorithm which has been successful in
minimizing complications related to the use of percutaneous closure devices.
Introduction: The following algorithm was implemented as follows:
Perclose was the default closure device used, except in cases where the artery
was very calcified or had dense scar tissue, in which case the Angioseal was
the first choice. If a Perclose failed, the Angioseal was attempted. If an
Angioseal failed, pressure was held for 15-30 minutes without peeking. If
holding pressure failed, a Femostop (Radi Medical) was applied.
Methods: The author made 201 punctures in 191 (103 male, 88
female) patients undergoing endovascular procedures from April 2006 to
October 2008. Risk factors included arrhythmia (n12, 6.28%), coronary
artery disease (n55, 28.80%), congestive heart failure (n9, 4.71%),
diabetes (n73, 38.22%), dialysis (n9, 4.71%), hyperlipidemia (n43,
22.51%), hypertension (n119, 62.30%), COPD (n13, 6.81%), history of
MI (n26, 13.61%), TIA/CVA (n7, 3.66%). ASA classifications were I
(n9, 4.71%), II (n35, 18.32%), III (n115, 60.21%) and IV (n23,
12.04%). Failure of the closure device was defined as persistent bleeding
requiring manual pressure, formation of a hematoma, blood transfusion, or
hospitalization. Failure of the algorithm was defined as formation of a
hematoma, blood transfusion or hospitalization.
Results: Perclose was selected as the first choice in 78.11% (n157) of
punctures and the Angioseal was selected in 17.80% (n44). The failure rate
for each device was 15.91% (n7) for Angioseal and 8.92% (n14) for
Perclose. The overall failure rate was 10.45%. All Angioseal failures were
successfully treated with manual compression. Perclose failures were ulti-
mately treated with an attempt at another closure device (n6), manual
compression (n6), or a Femostop (n2). Average recovery time was 1
hour 37 minutes (range: 23 minutes to 4 hours 48 minutes; SD: 39
minutes). 99.48% (n190) of patients were discharged same day; 0.52%
(n1) was admitted for thromboemboli. The final failure rate of the
algorithm was zero.
Conclusion: The described algorithm minimizes closure device-re-
lated complications. Implementation of this algorithm increases the safety of
performing endovascular interventions in an office angiosuite.
Author Disclosures: S.S. Ahn, Vascular Management Associates; J.F.
Chen, Vascular Management Associates; C. Kim, None; K. Peng, Vascular
Management Associates.
PP41.
Long Term Results of Open Versus Endovascular Revascularization of
Superficial Femoral Artery Occlusive Disease: A Case Control Series
Eva M Rzucidlo1, Aja Bjerke2, Daniel Walsh1, Richard Powell1. 1Dart-
mouth Hitchcock Medical Center, Lebanon, NH; 2Dartmouth Medical
School, Hanover, NH
Background: For patients with superficial femoral artery (SFA) occlu-
sive disease the most appropriate treatment has yet to be determined. We
performed a case control comparison of long term results of femoral popli-
teal bypass and SFA endovascular interventions to examine the characteris-
tics of patients and procedures to optimize results.Methods: All femoral-popliteal bypasses and SFA interventions per-
formed for consecutive patients with symptoms Rutherford 3 to 6 between
2001 and 2008 were reviewed. Kaplan Meir survival analyses were per-
formed to assess time-dependent outcomes. Log rank analyses, univariate
and multivariate analyses were performed.
Results: During the study period 152 limbs in 141 patients (66%male,
mean age 6622 years) underwent femoral-popliteal bypass; 233 limbs in
204 patients (49% male, mean age 70 11 years) underwent SFA interven-
tion. Surgery was performed less commonly for claudication (46% vs. 56%),
and more commonly for critical ischemia (54% vs 44%). Six year primary,
primary assisted and secondary patency rates were 56%, 64% and 75%
respectively for bypass patients. Six year primary, primary assisted and
secondary patency rates were 40%, 67% and 85% respectively for SFA
interventions. Six years limb salvage for surgery was 80%; six year limb
salvage rate was 92% for SFA interventions. Complications occurred in 21%
in the surgery group and in 1.2% of the endovascular group. Re-intervention
was required in 24% of surgery patients and in 14% of endovascular patients.
Failure of SFA intervention led to bypass in 5% of patients, however prior
failed intervention did not change target artery. Predictors of failed patency
for both the surgery and SFA intervention group were female gender,
diabetes, creatinine 1.8, and critical limb ischemia. However, limb salvage
was no different for all groups.
Conclusions: Though long term patency and limb salvage were equiv-
alent in this case controlled study of femoral popliteal bypass versus SFA
interventions, re-inventions and complications occurred at a higher rate in
the surgery group. Women, diabetics and renal failure patients had sustained
patency less frequently with both treatments; however, limb salvage was not
disadvantaged for any group. SFA stent placement should therefore be initial
therapy for patients with SFA occlusive disease.
Author Disclosures: E.M. Rzucidlo, None; A. Bjerke, None; D. Walsh,
None; R. Powell, None.
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Blood Transfusion is Associated With Increased Morbidity and Mor-
tality After Lower Extremity Revascularization
Eleftherios S Xenos1,2, Daniel Davenport1, Nick Abedi1, David JMinion1,2,
Ehab Sorial1, Shane O’Keeffe1, Eric D Endean1,2. 1University of Kentucky
Medical Center, Lexington, KY; 2VA Medical Center, Lexington, KY
Background: In adult ICU, trauma, and surgical patients, blood
transfusion is associated with increased morbidity and mortality as well as
increased risk of venous /arterial thrombotic events and mortality in hospi-
talized cancer patients. We analyzed data from the NSQIP database to
examine the effect of intraoperative blood transfusion in patients undergo-
ing lower extremity revascularization( LER).
Methods: We queried the ACS NSQIP database from 2005 to 2007.
CPT codes were used to identify LER procedures which were grouped into
thromboendarterectomy(TEA), bypass with vein(BV) or prosthetic graft
(BP). Multivariable analysis adjusted transfusion impact for clinical risk
factors, procedure group and complexity.
Results:Our query resulted in 8799 patients, 66.8 12.0 years of age,
of whom5569 (63.3%) weremale. 12% underwent TEA, 42% underwent BP
and 46% underwent BV. Composite mortality was 2.9%, morbidity 25.5%.
Transfusion rates varied across procedure group from 14.5% in TEA pa-
tients, 20.1% in BV patients, to 27.1% in BP patients. Intraoperative trans-
fusion was associated with increased morbidity and mortality; after adjust-
ment for clinical risk factors, procedure type and complexity, transfusion
remained significantly predictive of poorer outcomes:
Table. 30-day outcomes for lower extremity
revascularization; patients transfused intraoperatively
versus not. Unadjusted rates and odds ratios adjusted for
all significant ACS NSQIP clinical risk factors, procedure
group and complexity
Outcome Not transfused Transfused P-value
Adjusted odds
ratio (95%
CI) P-value
N/ % 6827/77.6% 1971/22.4%
Mortality 1.9 6.2 .001 2.2 (1.6-2.9) .001
Morbidity 21.7 38.8 .001 1.7 (1.5-2.0) .001
Graft Failure 4.8 7.8 .001 1.4 (1.2-1.8) .001
Return to O.R. 15.4 26.8 .001 1.5 (1.3-1.7) .001
Wound Complication 10.5 14.4 .001 1.3 (1.1-1.6) .001
Sepsis/Shock 5.0 12.9 .001 1.9 (1.6-2.3) .001
Pulmonary Complication 3.5 14.5 .001 3.0 (2.5-3.7) .001
Renal Insuff./Failure 1.0 3.0 .001 1.9 (1.3-2.8) .002
